Open AccessS770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study
Author(s) -
Edward V. Loftus,
Silvio Danese,
Remo Panaccione,
Timothy Hoops,
James Izanec,
Tony Ma,
Zhijie Ding,
Erik Muser,
Christopher Gasink,
Peter Irving,
Matthieu Allez,
William J. Sandborn
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776612.28121.af
Subject(s) - medicine , adalimumab , quality of life (healthcare) , ustekinumab , crohn's disease , randomized controlled trial , inflammatory bowel disease , physical therapy , adverse effect , disease , nursing